Results 91 to 100 of about 48,625 (267)

Menopausal hormone therapy after ovarian cancer: A 10‐year survival analysis in premenopausal women

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Among premenopausal women surgically treated for ovarian cancer, no difference in 10‐year overall survival was observed between postoperative MHT users and non‐users. Young ovarian cancer survivors should be recommended MHT after surgically induced menopause.
Åsa Ehlin von Kartaschew, Pernilla Dahm‐Kähler, Kenny Rodriguez Wallberg, Erik Holmberg, Angelique Flöter‐Rådestad   +4 more
wiley   +1 more source

Daily supplement of sesame oil prevents postmenopausal osteoporosis via maintaining serum estrogen and aromatase levels in rats

Scientific Reports
Estrogen deficiency is one of the main causes of postmenopausal osteoporosis in elderly women. Hormone replacement therapy has been employed to manage postmenopausal osteoporosis; however, it has raised concerns related to heart attacks and breast cancer.
Che-Chia Hsu, Po-Yen Ko, Ting-Hsien Kwan, Ming-Yie Liu, I.-Ming Jou, Chi-Wei Lin, Po-Ting Wu   +6 more
doaj   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Estimating the prevalence of osteoporosis in Australia [PDF]

, 2014
This report presents information about the prevalence and impact of osteoporosis in Australians aged 50 and over. Summary Osteoporosis, a common condition among older people, causes bones to become weak.

core  

Deciphering epigenetic regulation in postmenopausal osteoporosis: Current and future perspectives

View
Postmenopausal osteoporosis is the most prevalent form of osteoporosis, affecting approximately 33% of postmenopausal women globally and representing a major cause of age‐related disability and mortality.
Xiumei Tang, Meiru Chen, Guixuan Xu, Yuan Li, Sen Guo, Yufeng Huang, Zhaoliang Hou, Xiaoling Hou, Zhijian Wei, Wenzhao Wang, Bing Ning   +10 more
doaj   +1 more source

Impact of triglyceride/glucose index on bone mineral density and spinal alignment in postmenopausal osteoporosis

Medicine Science
Osteoporosis is a prevalent skeletal disorder characterized by decreased bone mineral density and an increased risk of fractures, particularly in postmenopausal women.
Kenan Bentli, Can Demirel
doaj   +1 more source

PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice

Experimental and Molecular Medicine, 2018
Osteoporosis: protein trigger for postmenopausal bone loss identified A protein that helps trigger bone loss in postmenopausal osteoporosis could be a potential therapeutic target.
Joo-Hee Choi, Ah-Ra Jang, Dong-il Kim, Min-Jung Park, Seul-Ki Lim, Myung-Sun Kim, Jong-Hwan Park   +6 more
doaj   +1 more source

Lifestyle Management in Menopause: A Systematic Review of Women With Premature Ovarian Insufficiency

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Premature ovarian insufficiency (POI), the loss of ovarian function before age 40, increases the risk of cardiovascular disease, low bone mineral density, dementia and psychological distress. Lifestyle interventions reduce chronic disease risk in other populations and, with hormone therapy, may improve health outcomes in POI.
Ladan Yeganeh, Nathalie Vermeulen, Carolyn Ee, Helena Teede, Amanda J. Vincent   +4 more
wiley   +1 more source

The Effect of Continous or Intermittent Calcitonin in the Treatment of Postmenopausal Osteoporosis

, 2002
The aim of this study was to compare the efficacy of continuous and intermittent salmon calcitonin in the treatment of postmenopausal osteoporosis. Sixty-eight women with postmenopausal osteoporosis were randomized to 2 treatment groups. The first group
F. Taşçıoğlu, C. Öner, O. Armağan
core  

YTHDF3 Enhances Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells in Osteoporosis by Promoting TBX19 Expression

Cell Proliferation, EarlyView.
In this study, OP‐BMSCs were successfully isolated from OVX osteoporotic rats. Mechanistic investigations revealed that the RNA‐binding protein YTHDF3 significantly upregulates Tbx19 expression by enhancing the stability of Tbx19 mRNA. Elevated Tbx19 levels, in turn, activate key osteogenic molecules, effectively promoting the differentiation of OP ...
Qianke Tao, Qiaonan Ye, Chengpeng Yang, Yuping Xie, Xuemei Long, Long Bai, Zhiyuan Zhang, Qianwei Li, Dan Tan, Jingang Xiao   +9 more
wiley   +1 more source